ArticleVeterinary medicine international2026
A Pilot Study Investigating the Clinically Significant Association Between Overweight, Hyperlipidemia, and Insulin Resistance in Dogs With Chronic Liver Disease.
Article in Veterinary medicine international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A Pilot Study Investigating the Clinically Significant Association Between Overweight, Hyperlipidemia, and Insulin Resistance in Dogs With Chronic Liver Disease.Veterinary medicine international · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The liver plays a central role in glucose and lipid metabolism. In human medicine, glucose metabolism alterations and insulin resistance are commonly associated with chronic liver disease (CLD), particularly in metabolic dysfunction-associated steatotic liver disease (MASLD). In veterinary medicine, however, the role of glucose metabolism in CLD remains poorly understood. We enrolled 67 client-owned dogs, including healthy controls, hepatopathic dogs with (metabolic hepatopathy [MH]) or without (non-metabolic hepatopathy [non-MH]) metabolic factors such as overweight and hyperlipidemia, chronic kidney disease (CKD) dogs, and hyperlipidemic CKD (CKD HL) dogs. We measured serum liver enzymes, triglycerides, cholesterol, glucose, fructosamine, and insulin. Insulin resistance was assessed using the homeostasis model assessment for insulin resistance index (HOMA-IR). Our findings revealed significantly elevated HOMA-IR values in MH dogs compared to all other groups (median: MH-6.89; non-MH-3.71; CKD-2.19; CKD HL-1.36; healthy-3.20). This increase occurred despite no significant differences in serum glucose and fructosamine concentrations. Results suggest the presence of insulin resistance in dogs with MH. HOMA-IR was not correlated with liver biochemical parameters (ALT, ALP, and bilirubin) but showed a positive correlation with hypertriglyceridemia. As this is a pilot study, further research is needed to clarify the role of insulin resistance in canine hepatopathies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.